FindTrial
Sign In

BI 770371

DRUG4 trials

Sponsors

Boehringer Ingelheim

Conditions

Carcinoma, Squamous Cell of Head and Neck (HNSCC)Compensated Liver CirrhosisHead and Neck Squamous Cell CarcinomaMelanomaMetabolic Dysfunction Associated Steatohepatitis (MASH)Non-small Cell Lung Cancer (NSCLC)Solid Tumors

Phase 1

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Active, not recruitingNCT05068102
Boehringer IngelheimCarcinoma, Squamous Cell of Head and Neck (HNSCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
Start: 2022-03-03End: 2026-05-31Updated: 2026-02-18
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Active, not recruitingNCT05327946
Boehringer IngelheimSolid Tumors
Start: 2022-05-17End: 2026-09-30Updated: 2025-10-28
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
RecruitingNCT06806852
Boehringer IngelheimHead and Neck Squamous Cell Carcinoma
Start: 2025-05-14End: 2027-07-31Target: 90Updated: 2026-04-01

Phase 2

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
CompletedNCT06675929
Boehringer IngelheimCompensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
Start: 2025-01-20End: 2026-01-13Updated: 2026-04-03

Related Papers

An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors.
Journal of Clinical Oncology2025-05-28